[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341741-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-341741-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","immune-checkpoint-inhibitors-for-pediatric-cancers-is-it-still-a-stalemate","Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?","","Immune checkpoint inhibitors (ICIs) for pediatric cancers are rapidly evolving as clinical knowledge expands. ICIs enhance natural antitumor immunity by counteracting suppressed immune pathways, and adult cancer benefit is well established. Yet early phase I/II trials limited to pediatric malignancies have shown modest results, with stronger responses largely confined to pediatric classic Hodgkin lymphoma. The review highlights differences in tumor immunogenicity, including fewer neoantigens in childhood cancers, while noting promising efficacy in hypermutated and SMARCB1-deficient subsets.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-checkpoint-inhibitors-for-pediatric-cancers-is-it-still-a-stalemate/341741/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-checkpoint-inhibitors-for-pediatric-cancers-is-it-still-a-stalemate/341741.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"How do the review’s biological explanations connect to ICI effectiveness?","Question",{"text":63,"@type":64},"ICIs act by restoring or enhancing immune responses against tumors. The review links potential efficacy to biological factors that promote neoantigen expression and inflammation within specific pediatric tumor subsets.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},341741,1790533799,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,97,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},"Technology",50,"technology",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},7,"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":131,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":12,"update_tm":135,"read_time":136,"preview_page_count":33,"preview_urls":137},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","pharmaceuticals  \nReview  \nImmune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?  \nTang-Her Jaing 1, *, Yi-Lun Wang 1 and Chia-Chi Chiu 2  \nCitation: Jaing, T.-H.; Wang, Y.-L.; Chiu, C.-C. Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate? Pharmaceuticals 2024, 17, 991. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ph17080991  \nAcademic Editors: Elena Y. Enioutina and Christof Vulsteke  \nReceived: 18 May 2024  \nRevised: 11 July 2024  \nAccepted: 24 July 2024  \nPublished: 26 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Hematology and Oncology, Department of Pediatrics, Chang Gung Memorial Hospital,  \n5 Fu-Shin Street, Kwei-Shan, Taoyuan 33315, Taiwan, China; [g987669@gmail.com](g987669@gmail.com)  \n[2](2 Division of Nursing)[ Division of Nursing](2 Division of Nursing), [Chang Gung Memorial Hospital](Chang Gung Memorial Hospital), [5 Fu-Shin Street](5 Fu-Shin Street), [Kwei-Shan](Kwei-Shan), Taoyuan 33315, Taiwan, China; [chi0105@cgmh.org.tw](chi0105@cgmh.org.tw)  \n* [Correspondence: jaing001@cgmh.org.tw](Correspondence: jaing001@cgmh.org.tw); Tel.: +886-3328-1200  \nAbstract: The knowledge surrounding the application of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers is continuously expanding and evolving. These therapies work by enhancing the body’s natural immune response against tumors, which may have been suppressed by certain pathways. The effectiveness of ICIs in treating adult cancers has been widely acknowledged. However, the results of early phase I/II clinical trials that exclusively targeted the use of ICIs for treating different pediatric cancers have been underwhelming. The response rates to ICIs have generally been modest, except for cases of pediatric classic Hodgkin lymphoma. There seems to be a notable disparity in the immunogenicity of childhood cancers compared to adult cancers, potentially accounting for this phenomenon. On average, childhood cancers tend to have significantly fewer neoantigens. In recent times, there has been a renewed sense of optimism regarding the potential benefits of ICI therapies for specific groups of children with cancer. In initial research, individuals diagnosed with pediatric hypermutated and SMARCB1-deficient cancers have shown remarkable positive outcomes when treated with ICI therapies. This is likely due to the underlying biological factors that promote the expression of neoantigens and inflammation within the tumor. Ongoing trials are diligently assessing the effectiveness of ICIs for pediatric cancer patients in these specific subsets. This review aimed to analyze the safety and effectiveness of ICIs in pediatric patients with different types of highly advanced malignancies.  \nKeywords: immune checkpoint inhibitors; pediatric cancer; hypermutated; SMARCB1-deficient  \n1. Introduction  \nThe main focus of cytotoxic chemotherapy and targeted therapies is to specifically attack cancer cells. However, immune checkpoint inhibitors (ICIs) function by enhancing the body’s immune response against tumors by interfering with co-inhibitory T-cell signaling. Resistance is a common occurrence in patients receiving both conventional cancer treatments and targeted therapies. Nevertheless, a considerable portion of patients who undergo ICI treatment exhibit enduring responses, suggesting the presence of a lasting immunologic memory.  \nICIs have completely transformed the way adult cancers are treated [1] . Following its approval in 2011, the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody has been utilized for the treatment of metastatic melanoma;","cbCaidg916cuXVX2","https://ap.wps.com/l/cbCaidg916cuXVX2","pdf",4095882,"English","# Introduction\n## Exploring the Biological Role of CTLA-4 and PD-1","[{\"question\":\"How do the review’s biological explanations connect to ICI effectiveness?\",\"answer\":\"ICIs act by restoring or enhancing immune responses against tumors. The review links potential efficacy to biological factors that promote neoantigen expression and inflammation within specific pediatric tumor subsets.\"}]","Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate? | PDF",1790043479,48,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/576001f56615df264baef0cfaad46e19.webp",983,1390,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76557c392170fdefaafb12e53dba6795.webp",982,1388,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bcab073f3e638ed4c4af4287f7393d0.webp",981,1387,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ff381446dccfdc7eecd76d18989e82a.webp",980,1385]